Exelixis (EXEL) Receivables - Net (2012 - 2026)
Exelixis (EXEL) recorded quarterly Receivables - Net of $328.9 million in Q2 2026, up 14.65% quarter-over-quarter from $286.9 million in Q1 2026, and up 16.8% on a YoY basis from $281.6 million in Q2 2025.
Exelixis (EXEL) Receivables - Net (2012 - 2026) Analysis & Trends
Exelixis' Receivables - Net history runs 15 years deep, the most recent figure standing at $328.9 million for Q2 2026.
- In Q2 2026, Receivables - Net rose 16.8% year-over-year to $328.9 million; the TTM figure through Apr 2026 stood at $328.9 million (up 16.8% YoY), while the FY2026 annual figure was $286.9 million, up 8.09% from the prior year.
- Receivables - Net was $328.9 million for Q2 2026 at Exelixis, up from $286.9 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $396.6 million in Q2 2024 to a low of $190.6 million in Q2 2022.
- Historically, Receivables - Net has averaged $263.5 million across 5 years, with a median of $248.1 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Receivables - Net jumped 70.34% in 2024, then slipped 26.28% in 2025.
- A 5-year view of Receivables - Net shows it stood at $214.8 million in 2022, then increased by 10.53% to $237.4 million in 2023, then climbed by 13.6% to $269.7 million in 2024, then climbed by 14.84% to $309.7 million in 2025, then advanced by 6.21% to $328.9 million in 2026.
- The last three Receivables - Net figures came in at $328.9 million (Q2 2026), $286.9 million (Q1 2026), and $309.7 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 328.95 Mn |
| Apr 3, 2026 | 328.95 Mn |
| Jan 2, 2026 | 286.92 Mn |
| Jan 2, 2026 | 286.92 Mn |
| Oct 3, 2025 | 309.73 Mn |
| Oct 3, 2025 | 309.73 Mn |
| Jul 4, 2025 | 292.35 Mn |
| Jul 4, 2025 | 292.35 Mn |
| Apr 4, 2025 | 281.64 Mn |
| Apr 4, 2025 | 281.64 Mn |
| Jan 3, 2025 | 265.44 Mn |
| Jan 3, 2025 | 265.44 Mn |
| Sep 27, 2024 | 269.71 Mn |
| Sep 27, 2024 | 269.71 Mn |
| Jun 28, 2024 | 396.58 Mn |
| Jun 28, 2024 | 396.58 Mn |
| Mar 29, 2024 | 240.58 Mn |
| Mar 29, 2024 | 240.58 Mn |
| Dec 29, 2023 | 237.41 Mn |
| Dec 29, 2023 | 237.41 Mn |